profit from every $100 of sales.
$0$100
Aptevo Therapeutics
$1.13-8.87% today
-95.7% in 1 year
1-year low $1.131-year high $28.08
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
You pay $0.30 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Aptevo Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $3.11 million in 2022 to $0 in 2025, with -$26.0 million of profit last year.
SalesProfit
Aptevo Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Aptevo Therapeutics | 0.3× · Cheap | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Aptevo Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 3 | 0 | 0 | 0 | |
| – | – | – | – | |
| -29 | -29 | -25 | -26 | |
| -28 | -28 | -24 | -26 | |
| 8 | -17 | -24 | -26 | |
| 729,727.27 | -527,606.06 | -31,460.23 | -87.27 | |
| – | – | – | – | |
| -919.7% | – | – | – | |
| 257.8% | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 34 | 25 | 16 | 27 |
| Cash | 23 | 17 | 9 | 22 |
| Total debt | 10 | 5 | 5 | 5 |
| Total liabilities | 16 | 13 | 11 | 10 |
| 18 | 12 | 5 | 17 | |
| 0 | 0 | 0 | 0 | |
| -82.3% | -129.5% | -191.4% | -94.4% | |
| 44.7% | -142.5% | -507.5% | -149.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -21 | -12 | -24 | -26 | |
| 0 | – | – | – | |
| -21 | -12 | -24 | -26 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 2 | 1 | 0 |
Valuation
- 0.3×
- –
- –
- 0.3×
- 0.8×
- –
- –
- -881.5%
- 336.1%
- 0.0%
Profitability
- 0.0%
- -919.7%
- 257.8%
- 0.0%
- -96.8%
- -127.6%
- -260.8%
- -95.5%
- -124.4%
- –
Growth
- –
- –
- −7.6%
- –
- +2,961.2%
Financial health
- -0.5×
- 0.27
- 17.0%
- –
- 3.82
- 3.82
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 948
Top 1%of 560
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -6.41 | -5.60 | −14.5% |
| Mar 20, 2026 | 1,684.47 | -8.09 | +20,921.6% |
| Nov 6, 2025 | -40.11 | -37.59 | −6.7% |
| Aug 11, 2025 | -151.08 | -0.45 | −33,473.3% |
| May 15, 2025 | -1,579.14 | -1,514.39 | −4.3% |
| Mar 4, 2025 | -82.37 | -7.75 | −962.8% |
| Nov 7, 2024 | -6,255.86 | -7,428.84 | +15.8% |
| Aug 8, 2024 | -21,765.20 | -25,153.79 | +13.5% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
50No pass
Benjamin Graham
85Pass
Philip Fisher
52No pass
Peter Lynch
93Pass
Joel Greenblatt
2No pass
Charlie Munger
46No pass
Terry Smith
42No pass
Questions about Aptevo Therapeutics
Is Aptevo Therapeutics a good stock to buy?
A strong, very profitable business, and the price looks low. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Aptevo Therapeutics AI analysis
What does Aptevo Therapeutics do?
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It is in Biotechnology.
Does Aptevo Therapeutics pay a dividend?
No. Aptevo Therapeutics does not pay a dividend at the moment.
Is Aptevo Therapeutics stock halal?
No. Aptevo Therapeutics does not pass our halal screen: its debt is 194% of its market value, at or above the 33% limit. How we check
How has Aptevo Therapeutics stock done over the past year?
Down 95.7% over the past twelve months, to $1.13. It traded between $1.13 and $28.08 and is 96.0% below its high.
Who are Aptevo Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Aptevo Therapeutics's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.